Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
For patients with progressive or recurrent glioblastoma there is no standard therapy. One
strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done
by 2 regimens. Aim of this study is to compare these 2 dosing regimens concerning toxicity.
In study arm A patients receive temozolomide for one week, followed by a week without
temozolomide. In study arm B patients receive temozolomide for three weeks, followed by a
week without temozolomide. The regimen that is less toxic will be selected for further
evaluations.